Whole-genome sequencing of 108 neuroblastoma cases revealed TERT rearrangements in 23% of stage 3 and 4 cases regardless of MYCN amplification or ATRX mutations and also confirmed this to be an independent prognostic factor [60]. The gene discussed is MYCN; the disease is neuroblastoma.